A Shandong Luye Pharmaceutical Co. Ltd. patent discloses serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and viral infections.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Etnova Therapeutics Co. Ltd. has described gadolinium complexes reported to be useful for the treatment of stroke, ataxia, epilepsy, spinal cord injury, optic nerve injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Yonsei University has divulged protein kinase inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified EGFR (HER1; erbB1) wild-type and/or mutant inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer (NSCLC).

Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Suzhou Genhouse Bio Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer and more.

Scripps Research Institute has described nucleoside analogues acting as prodrugs reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sortina Pharma AB has divulged sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, Alzheimer's disease and Parkinson's disease.

Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has identified Pim kinase inhibitors reported to be useful for the treatment of cancer.